Does Rallies show Form 4 insider transactions for FDMT?

Yes. Rallies tracks FDMT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is FDMT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FDMT. It does not provide personalized investment advice.

FDMT (4D Molecular Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of May 21, 2026, FDMT trades at $8.49 with a market cap of $437.29M and a P/E ratio of -3.28. FDMT moved +0.89% today. Year to date, FDMT is +16.03%; over the trailing twelve months it is +120.00%. Its 52-week range spans $2.24 to $12.34. Analyst consensus is strong buy with an average price target of $29.00. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading FDMT stock inside the company?

Recent FDMT insider activity includes Gupta Ashoo sold 310, Gupta Ashoo sold 80, Gupta Ashoo sold 310, Gupta Ashoo sold 79, and Bizily Scott sold 1.64K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

FDMT Key Metrics

Key financial metrics for FDMT
Metric	Value
Price	$8.49
Market Cap	$437.29M
P/E Ratio	-3.28
EPS	$-2.57
Dividend Yield	0.00%
52-Week High	$12.34
52-Week Low	$2.24
Volume	59
Avg Volume	0
Revenue (TTM)	$88.24M
Net Income	$-160.90M
Gross Margin	0.00%

Recent FDMT Insider Trades

Gupta Ashoo sold 310 (~$2.67K) on Mar 20, 2026.
Gupta Ashoo sold 80 (~$688.8) on Mar 20, 2026.
Gupta Ashoo sold 310 (~$2.69K) on Dec 20, 2025.
Gupta Ashoo sold 79 (~$685.72) on Dec 20, 2025.
Bizily Scott sold 1.64K (~$17.82K) on Dec 16, 2025.

Latest FDMT News

4D Molecular Therapeutics Reports $458M Cash, Completes 523-Patient Phase 3 Enrollment — May 7, 2026
4D Molecular Therapeutics Posts $0.43 EPS, $85M Q4 Revenue Beat Expectations — Mar 19, 2026
4D Molecular Therapeutics Secures $514M Cash Runway, Otsuka $85M Deal — Mar 18, 2026
4D Molecular Therapeutics Completes Phase 3 Enrollment in 11 Months, Secures $33 Target — Feb 28, 2026
4D Molecular Therapeutics Grants 124,200 RSUs to Nine New Hires — Feb 13, 2026

FDMT Analyst Consensus

9 analysts cover FDMT: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.00.

Common questions about FDMT

Who is trading FDMT stock inside the company?: Recent FDMT insider activity includes Gupta Ashoo sold 310, Gupta Ashoo sold 80, Gupta Ashoo sold 310, Gupta Ashoo sold 79, and Bizily Scott sold 1.64K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for FDMT?: Yes. Rallies tracks FDMT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is FDMT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FDMT. It does not provide personalized investment advice.